PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma

PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma

Abstract Chimeric antigen receptor (CAR) T‐cell therapy is a promising treatment option for relapsed or refractory (R/R) large B‐cell lymphoma (LBCL). However, only a subset of patients will present long‐term benefit. In this study, we explored the potential of PET‐based radiomics to predict treatme...

Full description

Bibliographic Details
Main Authors: Marta Ligero, Marc Simó, Cecilia Carpio, Gloria Iacoboni, Maria Balaguer‐Montero, Victor Navarro, Mario Andres Sánchez‐Salinas, Sabela Bobillo, Ana Marín‐Niebla, Josu Iraola‐Truchuelo, Pau Abrisqueta, Roser Sala‐Llonch, Francesc Bosch, Raquel Perez‐Lopez, Pere Barba
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:eJHaem
Subjects:
CAR T cells
DLBCL
non‐Hodgkin lymphoma
PET
progression‐free survival
radiomics
Online Access:https://doi.org/10.1002/jha2.757

Internet

https://doi.org/10.1002/jha2.757

Similar Items